Currently Viewing
FDA Approves Aliqopa for Follicular Lymphoma Treatment
September 14, 2017 – Jason M. Broderick
Combination Therapy Could Revolutionize Melanoma Treatment
September 12, 2017 – Silas Inman
A Wave of Cancer Developments at ESMO
September 12, 2017 – Silas Inman
Cancer Trials With Positive Results Get More Media Play
September 12, 2017 – Katie Kosko
Heart Problems, Fracture Risk Greater With Extended Use of Aromatase Inhibitors to Treat Breast Cancer
September 12, 2017 – Katie Kosko
Increased Abdominal Fat Associated With Higher Cancer Risk
September 12, 2017 – Brielle Urciuoli
Poll: Were you warned about side effects?
September 12, 2017 – STAFF
Cancer Survivors Celebrate Life and Liberty
September 11, 2017 – Mindy Waizer
Breast Cancer Risk Nearly Cut in Half For Women With High Cholesterol
September 11, 2017 – Katie Kosko

FDA Approves Aliqopa for Follicular Lymphoma Treatment

Aliqopa (copanlisib) was granted FDA approval for the treatment of patients with relapsed follicular lymphoma who have received at least two least prior systemic therapies.
BY Jason M. Broderick
PUBLISHED September 14, 2017
Aliqopa (copanlisib) was granted FDA approval for the treatment of patients with relapsed follicular lymphoma who have received at least two least prior systemic therapies.

The approval of Aliqopa is based primarily on findings from the phase 2 CHRONOS-1 trial, which included patients with multiple types of lymphoma. In the study, 59 percent of patients achieved objective responses to the intravenous inhibitor of PI3K-alpha and delta. Responses were durable, and the median progression-free survival (PFS) approached one year.

“For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments,” Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, said in a statement. “Options are limited for these patients and today’s approval provides an additional choice for treatment, filling an unmet need for them.”

Aliqopa is an intravenous pan-class I PI3K inhibitor that has predominant activity against the PI3K-alpha and delta isoforms. The alpha isoform is broadly expressed and involved in insulin signaling and angiogenesis, as well as resistance mechanisms to lymphoma. The delta isoform is expressed by leukocytes and is involved in B-cell signaling, development, and survival.

Lymphoma subtypes included in the CHRONOS-1 study were follicular lymphoma (grades 1-3a), marginal zone lymphoma, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma (LHL)/Waldenstrom macroglobulinemia (WM). Eligible patients had relapsed or refractory disease and failure of at least two prior lines of therapy.

Patients received Aliqopa at 60 mg on days one, eight and 15, repeated every 28 days until disease progression or development of unacceptable toxicity. The primary endpoint was objective response by central review after a minimum of 16 weeks of treatment. Secondary endpoints included PFS, duration of response, overall survival, safety and quality of life.

Data analysis included 142 patients who had a median age of 63. The median time since the most recent disease progression was 8.3 months, and the study population had received a median of 3 prior regimens. All of the patients had prior exposure to Rituxan (rituximab) and one or more alkylating agents, and 60.6 percent had disease that was refractory to the last regimen received.

Across the lymphoma subgroups, 80.3 percent of the patients had advanced disease (stage 3 or 4) at enrollment. Follicular lymphoma was the dominant lymphoma subtype, accounting for 73.2 percent of the study population.

Patients remained on treatment for a median duration of 22 weeks, during which time they received a median of 5.5 cycles of therapy and 96 percent of planned Aliqopa doses.

All but a few patients had some degree of target lesion shrinkage in response to treatment with Aliqopa. Patients with all lymphoma subtypes had lesion shrinkage.

The 59.2 percent overall response rate included complete responses in 12.0 percent of patients and partial responses in 47.2 percent of patients. An additional 29.6 percent of patients had stable disease, resulting in a disease control rate of 85.9 percent. Objective response rates were 59 percent or higher across all lymphoma subtypes except LHL/WM, wherein 1 of 6 patients with the subtype achieved an objective response with Aliqopa.

The study population had a median PFS of 11.2 months. In the follicular lymphoma subgroup, the median PFS was also 11.2 months.

The most common adverse events (all grades) were hyperglycemia (48.6 percent), hypertension (28.9 percent) and decreased neutrophil count (24.6 percent). Grade 3 hyperglycemia occurred in 33.1 percent of patients and grade 4 in 7 percent. Grade 3 hypertension occurred in 22.5 percent. Grade 3 decreased neutrophil count occurred in 6.3 percent and grade 4 in 12.7 percent of the patients. The most common laboratory abnormalities were elevated liver enzymes, which was grade 1/2 in all but a few cases.

The accelerated approval of Aliqopa is contingent upon the results of a confirmatory trial.
 
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Lymphoma Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In